Description of Parkinson disease population in a neurological medical center in Cali, Colombia
PDF (Español)
HTML (Español)

Keywords

Parkinson disease
Epidemiology
Levodopa (MeSH)

Abstract

Introduction: After alzheimer dementia, Parkinson disease (PD) is the second most prevalent neurodegenerative disease worldwide. Although it is known that PD has a similar epidemiological and clinical behavior around the world we do not have local data that allow us to confirm this stament.
Objective: To describe the main sociodemographic and clinical features of the population with PD in a neurological medical center in Cali, Colombia.
Materials and methods: In the period of time from May 2009 to March 2010 we collected the clinical records of patients with PD. Sociodemographic, clinical and treatment related variables were analyzed.
Results: 83 clinical records were analyzed. 72.3 % were males, the mean age was 71 years with a mean disease duration of five years at the moment of the information collection. The symptoms started at the right body side in the 59.6% being tremor the most frequent in the 51.2%. The non-motor clinical manifestations were anxiety 34.2%, depressive symptoms 17.1% and sleep disturbances in 14.2% of the studied sample. 3.6% of the patients had family history of PD. Levodopa associated diskinesias were detected in 53.7%.
Conclusion: Regarding to motor symptoms our results are similar to those reported elsewhere, nevertheless when we compared our description of non motor manisfestations there exists lower prevalence of these complais. The former finding could be explained by a low suspicion index at the moment to asses this population. Further studies are necessaries.


PDF (Español)
HTML (Español)

References

GRUPO MBE GALICIA. Enfermedad de Parkinson. Guias clínicas. 2006; 6(23)

LONNEKE ML, DE LAU Y, BRETELER M. Epidemiology of Parkinson's disease. Lancet Neurology 2006;5:525-535.

TAKEUCHI Y, GUEVARA JG. Prevalencia de las enfermedades neurológicas en el Valle del Cauca. Estudio neuroepidemiologico nacional (EPINEURO). Colombia Med, 1999;30, 002: 74 - 81.

ARANGO GJ. Enfermedad de Parkinson en Colombia. Boletin Neuropilo. ACN, Junio 2007, Numero 16. Issn 1900 - 7035.

RODRIGUEZ-OROZ MC, JAHANSHAHI M], KRACK P, LITVAN I, MACIAS R, BEZARD E, OBESO JA. Initial Clinical manifestations of Parkinson's Disease: Features and Pathophysiological mechanisms. Lancet Neurol 2009; 8:1128-39.

MUÑOZ GARCÍA JE. Estudios de asociación Genética y detección de mutaciones en pacientes con Enfermedad de Parkinson. Comparación Genético-Clínica entre los casos esporádicos y familiares. Barcelona 2001, 194 P. Presentado en la Universidad de Barcelona para obtener el título de Doctor en Medicina.

CALABRESI P, DI FILIPPO M, GHIGLIERI V, TAMBASCO N, PICCONI B. Levodopa-induced dyskinesias in patients with Parkinson's Disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9:1106-17.

MARTIN WR, WIELER M. Treteatment of Parkinson's disease. Can. J. Neurol. Sci. 2003; 30 (supl 1): s27 - s33.

TARSY D. Non pharmacologic treatment of Parkinson's disease. [Monografía en Internet]. Walthman (MA: UpToDate; October 2005 [acceso 2 de mayo de 2006]. Disponible en: http://www.uptodate.com.

OLANOW CW, OBESO JA, STOCHI F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurology 2006;5:677-687.

LEÓN-SARMIENTO FE, PRADILLA G, PARDO CA, PUENTES F. The first neuroepidemiological study. Rev Panam Salud Publica/Pan Am J Public Health 2003;14(2): 109.

LEES AJ, SELIKHOVA M, WILLIAMS DR, KEMPSTER PA, HOLTON JL, REVESZ T. A clinicopathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.

MARRAS C, MCDERMOTT MP, MAREK K, ROCHON P, NAGLIE G, TANNER CM, RUDOLPH A, SHOULSON I, LANG AE; . Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 2011; 26: 608-613.

SHOULSON I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol. 1998; 44:S160-166.

LEWITT P, OAKES D, CUI L. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alphatocopherol. Mov Disord. 1997;12:183-189.

WITJAS T, KAPHAN E, AZULAY JP, ET AL. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413.

SHULMAN LM, TABACK RL, RABINSTEIN AA, WEINER WJ. Nonrecognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 193-197.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.